Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Almost all antipsychotics can induce dyslipidemia, but no treatment has been established.
Vildagliptin can improve lipid levels in obese patients. The investigators conducted a
randomized, placebo-controlled study to test the efficacy of vildagliptin for
antipsychotic-induced dyslipidemia.